Year: 2016
Type: review
Abstract: Anemia is an independent risk factor for adverse patient outcomes. There are no guidelines for management of anemia in patients with congestive heart failure (CHF), despite its high incidence. Four objectives were defined by the International Anemia Management and Clinical Outcomes Expert Panel (AMCO), a multinational group of interdisciplinary experts identified by the Society for the Advancement of Blood Management (SABM) to: determine the prevalence of anemia in outpatients; to determine the prevalence of hospital-acquired anemia; to assess the impact of anemia management on clinical outcomes such as quality of life and functional status; and to provide recommendations for primary care physicians and specialists for the diagnosis, evaluation, and management of anemia in patients with CHF. Anemia and iron deficiency were confirmed to be highly prevalent in patients with CHF. Intravenous iron therapy improves anemia, cardiac function and exercise tolerance, leading to improvement in quality of life. Anemia management has been demonstrated to be cost-effective. Clinical care pathways to manage anemia in patients with CHF are recommended as best practices in order to improve patient outcomes. Am. J. Hematol. 92:88-93, 2017. © 2016 Wiley Periodicals, Inc.
Source: American Journal of Hematology
DOI: 10.1002/ajh.24595
Institutions: Stanford Medicine, Stanford University, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Hospital Universitario Virgen del Rocío, Englewood Hospital and Medical Center, Pennsylvania Hospital, Abramson Cancer Center, Society of Hospital Medicine, Temple University, Hospital Del Mar, Municipal Institute for Medical Research, Hospital del Mar Research Institute, Acumen (United States), Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2541278733
